Necrosis News and Research

RSS

Scientists outline how future therapies could change type 1 diabetes care

Researchers writing in The Lancet review breakthroughs in type 1 diabetes treatment, from immunotherapies that delay onset to stem-cell β-cell replacement and automated insulin delivery. They stress that equitable access, validated surrogate endpoints, and scalable technologies are crucial for lasting impact.

24 Sep 2025

Targeting miR-378 could offer a dual-action strategy against osteoporosis

Osteoporosis is a degenerative disease characterized by decreased bone mass and damage to bone microarchitecture, as well as increased bone fragility.

23 Sep 2025

Long COVID linked to heavier periods and symptom flare-ups during menstruation

Researchers found that long COVID is linked to heavier, longer, and more irregular bleeding without disrupting ovulation. Symptom severity also peaks around menstruation, likely driven by hormonal and immune changes.

17 Sep 2025

Study reveals how ozone exerts multi-organ effects by disturbing the lung-liver connection

Ozone pollution is rising worldwide, frequently exceeding safety thresholds in urban centers and industrial regions. Its health risks are well-documented: breathing ozone can worsen asthma, damage airways, and increase the risk of cardiovascular and neurological disorders.

17 Sep 2025

How processed red meat might drive neurodegenerative diseases

The relationship between processed red meat and neurodegenerative diseases is complex, with potential risks and protective effects requiring more investigation.

15 Sep 2025

Novel RNA target offers hope for improving outcomes in patients with chronic limb ischemia

Mark W. Feinberg, MD, cardiologist with the Mass General Brigham Heart and Vascular Institute and professor of medicine at Harvard Medical School, is the senior author of a paper published in the Journal of Clinical Investigation, "A smooth muscle cell lncRNA controls angiogenesis in chronic limb-threatening ischemia through miR-143-3p/HHIP signaling."

13 Sep 2025

Citrus flavonoid hesperidin lowers oxidative damage in cell experiments

Researchers tested hesperidin extracted from citrus peels and found it reduced inflammatory cytokines and oxidative stress markers in cultured immune cells. The findings highlight hesperidin’s strong in vitro anti-inflammatory and antioxidant potential, warranting further in vivo research.

11 Sep 2025

How plant compounds could target Alzheimer’s disease from multiple angles

This review highlights how dietary polyphenols modulate Alzheimer’s disease biology through antioxidant, anti-inflammatory, and multi-target mechanisms, supported by in-silico docking analyses. Despite promise, challenges in bioavailability and brain delivery remain key hurdles to clinical translation.

31 Aug 2025

COVID-19 ages arteries prematurely with women most affected

COVID-19 may leave arteries biologically “older,” with women showing more persistent stiffness and symptom links than men. Findings from the large CARTESIAN cohort suggest this vascular aging effect is partly reversible over time.

19 Aug 2025

Researchers investigate how citrus bioflavonoid naringin could reduce inflammation and heart risk

Researchers reviewed 62 studies on naringin, a citrus flavonoid, and found strong preclinical evidence for its cardioprotective effects, including improved endothelial function, reduced oxidative stress, and protection against myocardial injury.

18 Aug 2025

Can ginger help diabetes? Major review says yes, it lowers blood sugar and inflammation effectively

A new systematic review of five meta-analyses confirms that ginger significantly reduces inflammation, lowers blood sugar and HbA1c in type 2 diabetes, and improves antioxidant status. It also effectively reduces nausea in pregnancy, though its impact on vomiting is less consistent.

17 Aug 2025

Targeting ferroptosis to eliminate therapy-resistant cancer stem cells

Recent advancements in cancer research are shedding light on a novel therapeutic strategy aimed at overcoming the formidable challenge of cancer stem cells (CSCs).

14 Aug 2025

Engineered CD40 antibody shrinks tumors and induces remission

Over the past 20 years, a class of cancer drugs called CD40 agonist antibodies have shown great promise-and induced great disappointment.

14 Aug 2025

New mouse model reveals key role of osteocytes in osteogenesis imperfecta

Osteogenesis imperfecta (OI) refers to a group of rare genetic bone disorders that results in the formation of fragile bones. In patients with OI, the matrix that makes up the bone has been found to be abnormal, leading to an increased risk of fractures.

13 Aug 2025

KAIST researchers link placental inflammation to childhood allergies

It is already well-known that when a mother experiences inflammation during pregnancy, her child is more likely to develop allergic diseases.

7 Aug 2025

Smart wound patch detects healing progress and infection risk

RMIT's Bluetooth-enabled flexible sensor patch monitors wound healing, detecting biomarkers and vital signs without dressing removal for improved patient care.

6 Aug 2025

Bacteria-based cancer therapy achieves tumor eradication without immune cells

A joint research team led by Professor Eijiro Miyako of the Japan Advanced Institute of Science and Technology (JAIST), in collaboration with Daiichi Sankyo Co., Ltd. and University of Tsukuba, has developed a groundbreaking immune-independent bacterial cancer therapy using a novel microbial consortium called AUN.

5 Aug 2025

Advanced form of AI opens door to personalized cancer care

What if a computer could read a patient's medical notes and help doctors determine important information for their treatment?

1 Aug 2025

How a leaky gut could be putting your heart at risk

Researchers reviewed recent studies showing that gut dysbiosis contributes to heart failure by weakening the gut barrier, enabling harmful metabolites like TMAO to trigger inflammation and cardiac damage. The review highlights a bidirectional “gut-heart axis” and points to new avenues for dietary and microbial therapies.

28 Jul 2025

Can one drug do it all? Reviewing the expanding clinical universe of GLP-1 agonists

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide significant benefits for cardiovascular, kidney, liver, joint, and sleep-related diseases. These effects extend beyond weight loss, suggesting anti-inflammatory mechanisms with broad potential for managing chronic diseases.

22 Jul 2025